This study explores the impact of interferon-free therapies on hepatitis C virus related hepatocellular carcinoma at a population level.
The goal of this study was to quantify the bias in estimating risk of hepatocellular carcinoma for patients with cirrhosis and cured hepatitis C.
We estimated HCV reinfection rates among PWID in Scotland pre and post-introduction of DAAs.
We conducted an external validation of six HCC prediction models for UK patients with cirrhosis HCV virological cure.
We assessed the impact of rapid DAA scale‐up to PWID delivered through community services in the Tayside region of Scotland.
We examined the impact of the introduction of direct-acting antiviral (DAA) therapies on hepatitis C related decompensated cirrhosis (DC) through analysis of population-based data from Scotland.
This is a protocol paper for a natural experiment that looks at the population impact of scaling up hepatitis C treatment with direct acting antiviral treatments as a way to prevent disease transmission and reduce prevalence/incidence among people who inject drugs.
This study provides one of the first epidemiological analyses of the association between NPS injecting and HCV among a population level sample of PWID.